Skip to main content
All lobbying filings

DLA PIPER LLP (US)

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Trade association of innovative biopharmaceutical research companies.

 Filing Registration
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Mar 17, 2025
Money reported
None
Registrations and no-activity reports carry no figure.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 3
  • RICHARD BURR Former member of Congress New on this filing
    Previously held: U.S. Senator
  • MARGARET MARTIN New on this filing
    Previously held: Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard Burr
  • RACHEL PORTMAN New on this filing
    Previously held: Deputy Health Policy Director, Committee on Senate Health, Education, Labor and Pensions; Health Policy Assistant, Sen. Richard Burr; Intern, Rep. Robert Portman

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Lobbying activity 6

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem